18.200 s

+0.410 (+2.30%)
Range - - -   (-%)
Open 18.200
Previous Close 17.790
Bid Price 24.130
Bid Volume 10
Ask Price 25.700
Ask Volume 8
Volume 1,531,606
Value -
Remark s
Delayed prices. Updated at 29 Mar 2024 04:00.
Data powered by
View All Events

About ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.

There are 5 followers

Followers
0
Followers
2
Followers
0
Followers
38
Followers
1